DiamondRock Hospitality (DRH) emerges as the more attractive value investment compared to National Health Investors (NHI). DRH has a superior Zacks Rank of #2 (Buy) versus NHI's #4 (Sell), along with better valuation metrics including a lower forward P/E ratio (10.35 vs 13.72) and a lower PEG ratio (1.65 vs 3.49). DRH also received a Value grade of B compared to NHI's D grade.

A comparison of two REIT stocks shows Cousins Properties (CUZ) as the superior value option compared to National Health Investors (NHI). CUZ has a stronger Zacks Rank of #2 (Buy) versus NHI's #4 (Sell), better valuation metrics including a lower forward P/E ratio of 9.96 vs 15.07, and a higher Value grade of B versus C.

National Health Investors, Inc. (NYSE:NHI) announced it will pay a second quarter 2026 dividend of $0.92 per common share on August 7, 2026, to stockholders of record as of June 30, 2026. The REIT focuses on senior housing communities and medical facilities through its Real Estate Investments and SHOP segments.

National Health Investors (NHI) has been on a downward trend, losing 10.2% over the past four weeks. However, the stock is now in oversold territory, and there is strong agreement among analysts that the company will report better earnings than previously predicted, indicating a potential turnaround.

Healthpeak Properties, Inc. (DOC) is well-positioned to benefit from its diversified healthcare real estate assets, particularly its lab and continuing care retirement community (CCRC) portfolios. However, it faces competition and challenges from a high-interest rate environment.

Does National Health Investors (NHI) have what it takes to be a top stock pick for momentum investors? Let's find out.

In the latest quarter, 4 analysts provided ratings for National Health Investors (NYSE:NHI), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $69.00, and a low estimate of $58.00. Observing a 7.14% increase, the current average has risen from the previous average price target of $60.67. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target James Feldman Wells Fargo Raises Overweight $69.00 $63.00 Michael Lewis Truist Securities Raises Hold $58.00 $55.00 Richard Anderson Wedbush Raises Outperform $66.00 $64.00 Juan Sanabria BMO Capital Announces Outperform $67.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information provides a ...Full story available on Benzinga.com

While the top- and bottom-line numbers for National Health Investors (NHI) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Innovative Industrial Properties (IIPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in FFO estimate revisions for the stock doesn't suggest further strength down the road.

Industrial Logistics Properties Trust (ILPT) delivered FFO and revenue surprises of 7.69% and 1.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

National Health Investors (NYSE:NHI) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 2 0 0 0 2M Ago 0 2 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated National Health Investors and provided 12-month price targets. The average target is $64.5, accompanied by a high estimate of $69.00 and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 11.69% increase from the previous average price target of $57.75. Analyzing Analyst Ratings: A Detailed Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Michael Lewis Truist Securities Raises Hold $58.00 $55.00 Richard Anderson Wedbush Raises Outperform $66.00 $64.00 Juan Sanabria BMO Capital Announces Outperform $67.00 - Richard Anderson Wedbush Raises Outperform $64.00 $57.00 Connor Siversky Wells Fargo Raises Overweight $63.00 $55.00 Omotayo Okusanya Deutsche Bank Announces Buy $69.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information offers ...Full story available on Benzinga.com

Technology stocks are experiencing surge in investment similar to dot-com boom of the late 90s. Click here for 2 individual bonds which are now easy to purchase.